Adriana Weinberg
Concepts (779)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
HIV Infections | 96 | 2023 | 2532 | 11.420 |
Why?
| Herpes Zoster Vaccine | 23 | 2023 | 159 | 9.600 |
Why?
| Herpes Zoster | 31 | 2023 | 334 | 8.970 |
Why?
| Herpesvirus 3, Human | 34 | 2023 | 391 | 7.120 |
Why?
| Influenza Vaccines | 29 | 2021 | 504 | 6.820 |
Why?
| Cytomegalovirus Infections | 26 | 2024 | 188 | 6.400 |
Why?
| Antibodies, Viral | 42 | 2021 | 551 | 6.210 |
Why?
| Immunity, Cellular | 32 | 2023 | 276 | 6.100 |
Why?
| Pregnancy Complications, Infectious | 24 | 2023 | 301 | 5.030 |
Why?
| Influenza, Human | 27 | 2021 | 566 | 4.640 |
Why?
| T-Lymphocytes, Regulatory | 14 | 2020 | 367 | 4.620 |
Why?
| Cytomegalovirus | 24 | 2024 | 144 | 4.560 |
Why?
| Antiretroviral Therapy, Highly Active | 22 | 2017 | 261 | 3.260 |
Why?
| Anti-HIV Agents | 18 | 2023 | 685 | 2.970 |
Why?
| Influenza A Virus, H1N1 Subtype | 13 | 2021 | 147 | 2.960 |
Why?
| Pneumococcal Infections | 4 | 2022 | 99 | 2.940 |
Why?
| T-Lymphocytes | 22 | 2020 | 1814 | 2.910 |
Why?
| T-Lymphocyte Subsets | 10 | 2019 | 409 | 2.830 |
Why?
| Immunologic Memory | 14 | 2020 | 321 | 2.820 |
Why?
| CD4-Positive T-Lymphocytes | 28 | 2023 | 1003 | 2.500 |
Why?
| Vaccines, Attenuated | 21 | 2023 | 114 | 2.490 |
Why?
| Vaccination | 22 | 2023 | 1241 | 1.970 |
Why?
| Respiratory Syncytial Virus, Human | 4 | 2021 | 61 | 1.940 |
Why?
| Antiviral Agents | 16 | 2023 | 670 | 1.800 |
Why?
| Leukocytes, Mononuclear | 14 | 2020 | 514 | 1.790 |
Why?
| Chickenpox | 7 | 2023 | 102 | 1.790 |
Why?
| Interferon-gamma | 19 | 2022 | 747 | 1.770 |
Why?
| Humans | 219 | 2024 | 122796 | 1.730 |
Why?
| Drug Resistance, Viral | 14 | 2017 | 99 | 1.720 |
Why?
| CD8-Positive T-Lymphocytes | 12 | 2019 | 715 | 1.690 |
Why?
| Female | 153 | 2023 | 63629 | 1.650 |
Why?
| HIV | 8 | 2022 | 219 | 1.650 |
Why?
| Chickenpox Vaccine | 10 | 2023 | 70 | 1.570 |
Why?
| Respiratory Tract Infections | 5 | 2018 | 335 | 1.540 |
Why?
| Tetanus Toxoid | 4 | 2021 | 38 | 1.510 |
Why?
| Infectious Disease Transmission, Vertical | 10 | 2023 | 159 | 1.480 |
Why?
| Virus Shedding | 6 | 2017 | 47 | 1.480 |
Why?
| Pregnancy | 41 | 2023 | 5854 | 1.430 |
Why?
| Virus Diseases | 3 | 2018 | 201 | 1.390 |
Why?
| Tumor Necrosis Factor Receptor Superfamily, Member 7 | 9 | 2009 | 28 | 1.380 |
Why?
| Hepatitis A Vaccines | 5 | 2020 | 16 | 1.340 |
Why?
| Influenza A virus | 8 | 2013 | 112 | 1.330 |
Why?
| Influenza B virus | 8 | 2017 | 33 | 1.320 |
Why?
| Antibodies, Bacterial | 5 | 2022 | 129 | 1.310 |
Why?
| Cord Blood Stem Cell Transplantation | 3 | 2023 | 96 | 1.260 |
Why?
| Adjuvants, Immunologic | 8 | 2021 | 211 | 1.260 |
Why?
| Infant | 39 | 2023 | 8523 | 1.260 |
Why?
| Adult | 89 | 2024 | 32385 | 1.230 |
Why?
| Dermatitis, Atopic | 5 | 2020 | 342 | 1.230 |
Why?
| B-Lymphocytes | 7 | 2021 | 936 | 1.220 |
Why?
| HIV-1 | 13 | 2019 | 783 | 1.210 |
Why?
| Male | 116 | 2023 | 59639 | 1.210 |
Why?
| CD4 Lymphocyte Count | 17 | 2019 | 274 | 1.180 |
Why?
| Hemagglutination Inhibition Tests | 14 | 2021 | 38 | 1.150 |
Why?
| Antibody Formation | 7 | 2023 | 285 | 1.150 |
Why?
| Anti-Retroviral Agents | 8 | 2023 | 208 | 1.130 |
Why?
| DNA, Viral | 11 | 2018 | 358 | 1.130 |
Why?
| Breast Feeding | 4 | 2023 | 398 | 1.110 |
Why?
| Pneumococcal Vaccines | 3 | 2022 | 141 | 1.100 |
Why?
| Lymphocyte Activation | 25 | 2020 | 1148 | 1.090 |
Why?
| Interleukin-2 | 12 | 2022 | 420 | 1.050 |
Why?
| Hematopoietic Stem Cell Transplantation | 3 | 2023 | 543 | 1.050 |
Why?
| Viral Load | 18 | 2023 | 423 | 1.030 |
Why?
| Vaccines, Synthetic | 6 | 2023 | 130 | 1.030 |
Why?
| Vaccines, Inactivated | 10 | 2017 | 68 | 1.030 |
Why?
| Viremia | 9 | 2021 | 133 | 1.020 |
Why?
| Enzyme-Linked Immunospot Assay | 6 | 2018 | 33 | 1.020 |
Why?
| HIV Protease Inhibitors | 3 | 2019 | 65 | 0.960 |
Why?
| Papillomavirus Vaccines | 3 | 2018 | 221 | 0.950 |
Why?
| Immune Reconstitution | 1 | 2023 | 6 | 0.940 |
Why?
| Environmental Exposure | 2 | 2018 | 427 | 0.920 |
Why?
| Double-Blind Method | 17 | 2021 | 1711 | 0.870 |
Why?
| Child, Preschool | 32 | 2022 | 9755 | 0.860 |
Why?
| Child | 50 | 2023 | 19561 | 0.850 |
Why?
| Herpesvirus 1, Human | 3 | 2016 | 82 | 0.850 |
Why?
| Young Adult | 29 | 2023 | 11094 | 0.850 |
Why?
| Receptors, Tumor Necrosis Factor | 8 | 2001 | 148 | 0.840 |
Why?
| Middle Aged | 59 | 2023 | 28563 | 0.840 |
Why?
| Orthomyxoviridae | 3 | 2017 | 38 | 0.810 |
Why?
| Infant, Newborn | 21 | 2023 | 5430 | 0.790 |
Why?
| Aged, 80 and over | 18 | 2022 | 6845 | 0.790 |
Why?
| Adolescent | 50 | 2023 | 18948 | 0.780 |
Why?
| Latent Tuberculosis | 1 | 2021 | 63 | 0.770 |
Why?
| DNA-Directed DNA Polymerase | 4 | 2008 | 45 | 0.760 |
Why?
| Epstein-Barr Virus Infections | 4 | 2013 | 73 | 0.750 |
Why?
| Aged | 39 | 2023 | 20495 | 0.740 |
Why?
| Rotavirus Vaccines | 2 | 2017 | 48 | 0.730 |
Why?
| Rotavirus Infections | 2 | 2017 | 55 | 0.720 |
Why?
| Immunosuppressive Agents | 6 | 2014 | 687 | 0.710 |
Why?
| Antibodies, Neutralizing | 7 | 2021 | 229 | 0.710 |
Why?
| Viral Envelope Proteins | 2 | 2021 | 81 | 0.700 |
Why?
| Herpesvirus 4, Human | 7 | 2014 | 127 | 0.700 |
Why?
| Respiratory Syncytial Virus Vaccines | 1 | 2019 | 24 | 0.690 |
Why?
| Medroxyprogesterone Acetate | 2 | 2016 | 30 | 0.690 |
Why?
| Tuberculosis | 5 | 2023 | 266 | 0.680 |
Why?
| Cytokines | 11 | 2022 | 1928 | 0.680 |
Why?
| Isoniazid | 5 | 2023 | 55 | 0.670 |
Why?
| Paramyxoviridae Infections | 2 | 2011 | 11 | 0.660 |
Why?
| Human papillomavirus 18 | 1 | 2018 | 14 | 0.660 |
Why?
| Human papillomavirus 16 | 1 | 2018 | 25 | 0.650 |
Why?
| Mycobacterium tuberculosis | 1 | 2021 | 304 | 0.650 |
Why?
| Cryopreservation | 2 | 2010 | 102 | 0.640 |
Why?
| Hepatitis A Antibodies | 2 | 2009 | 4 | 0.640 |
Why?
| AIDS-Related Opportunistic Infections | 3 | 2019 | 114 | 0.640 |
Why?
| Immunocompromised Host | 9 | 2019 | 205 | 0.640 |
Why?
| Hospitalization | 6 | 2021 | 1914 | 0.630 |
Why?
| Immunoconjugates | 2 | 2013 | 90 | 0.620 |
Why?
| Th1 Cells | 1 | 2018 | 138 | 0.620 |
Why?
| Lymphocyte Subsets | 2 | 2015 | 78 | 0.620 |
Why?
| Mutation | 7 | 2009 | 3493 | 0.610 |
Why?
| Simplexvirus | 8 | 2016 | 85 | 0.600 |
Why?
| Antigens, Viral | 8 | 2017 | 181 | 0.600 |
Why?
| Immunization, Secondary | 6 | 2017 | 86 | 0.600 |
Why?
| Age Factors | 9 | 2019 | 3114 | 0.590 |
Why?
| Encephalomyelitis, Autoimmune, Experimental | 5 | 1999 | 49 | 0.580 |
Why?
| Premature Birth | 2 | 2019 | 304 | 0.570 |
Why?
| Flow Cytometry | 10 | 2019 | 1128 | 0.570 |
Why?
| Viral Proteins | 4 | 2012 | 300 | 0.570 |
Why?
| Herpesviridae Infections | 5 | 2013 | 144 | 0.570 |
Why?
| Host-Pathogen Interactions | 1 | 2019 | 313 | 0.560 |
Why?
| Vitamin D | 1 | 2019 | 363 | 0.560 |
Why?
| Viral Vaccines | 4 | 2014 | 89 | 0.550 |
Why?
| Herpes Simplex | 4 | 2016 | 94 | 0.540 |
Why?
| T-Lymphocytes, Cytotoxic | 3 | 2011 | 160 | 0.530 |
Why?
| Gastrointestinal Microbiome | 1 | 2022 | 561 | 0.530 |
Why?
| Reagent Kits, Diagnostic | 2 | 2005 | 44 | 0.530 |
Why?
| Acyclovir | 5 | 2012 | 104 | 0.520 |
Why?
| Case-Control Studies | 12 | 2020 | 3296 | 0.520 |
Why?
| Central Nervous System Viral Diseases | 3 | 2004 | 62 | 0.520 |
Why?
| Contraceptive Agents, Female | 1 | 2016 | 65 | 0.520 |
Why?
| Immunoassay | 5 | 2017 | 101 | 0.500 |
Why?
| Immunoglobulin G | 7 | 2021 | 804 | 0.500 |
Why?
| Immunity, Mucosal | 2 | 2012 | 86 | 0.500 |
Why?
| Injections, Intramuscular | 4 | 2017 | 127 | 0.500 |
Why?
| B-Lymphocyte Subsets | 1 | 2015 | 81 | 0.490 |
Why?
| Foscarnet | 6 | 2008 | 19 | 0.490 |
Why?
| Immunophenotyping | 5 | 2019 | 288 | 0.480 |
Why?
| Postpartum Period | 5 | 2022 | 281 | 0.470 |
Why?
| Gene Expression Profiling | 3 | 2019 | 1625 | 0.460 |
Why?
| Antigen-Presenting Cells | 4 | 2022 | 157 | 0.460 |
Why?
| Polymerase Chain Reaction | 10 | 2023 | 1021 | 0.460 |
Why?
| Staphylococcus aureus | 1 | 2017 | 400 | 0.450 |
Why?
| B-Lymphocytes, Regulatory | 1 | 2013 | 5 | 0.450 |
Why?
| RNA, Viral | 7 | 2019 | 597 | 0.450 |
Why?
| CD4 Antigens | 2 | 2011 | 136 | 0.450 |
Why?
| Influenza A Virus, H3N2 Subtype | 4 | 2020 | 39 | 0.450 |
Why?
| Immune Tolerance | 2 | 2013 | 355 | 0.440 |
Why?
| Respiratory Syncytial Virus Infections | 1 | 2014 | 103 | 0.440 |
Why?
| Reverse Transcriptase Inhibitors | 3 | 2020 | 85 | 0.440 |
Why?
| Candida | 3 | 2010 | 36 | 0.430 |
Why?
| Alphapapillomavirus | 1 | 2012 | 38 | 0.430 |
Why?
| Cohort Studies | 11 | 2023 | 5294 | 0.430 |
Why?
| Hepatitis A | 1 | 2012 | 28 | 0.430 |
Why?
| Vaccines, Conjugate | 2 | 2022 | 62 | 0.430 |
Why?
| Cell Proliferation | 6 | 2020 | 2328 | 0.420 |
Why?
| Skin | 1 | 2017 | 694 | 0.420 |
Why?
| Placebos | 5 | 2017 | 204 | 0.420 |
Why?
| Transplant Recipients | 2 | 2024 | 149 | 0.420 |
Why?
| Polysaccharides | 2 | 2022 | 81 | 0.420 |
Why?
| CD28 Antigens | 3 | 2009 | 48 | 0.420 |
Why?
| Metapneumovirus | 1 | 2011 | 13 | 0.410 |
Why?
| Transplantation | 1 | 2011 | 26 | 0.410 |
Why?
| Contraceptive Agents | 1 | 2012 | 61 | 0.400 |
Why?
| Lymphocyte Count | 4 | 2019 | 141 | 0.400 |
Why?
| Herpesvirus 2, Human | 2 | 2012 | 32 | 0.400 |
Why?
| Lymphoproliferative Disorders | 1 | 2011 | 46 | 0.400 |
Why?
| Pregnancy Outcome | 7 | 2021 | 364 | 0.400 |
Why?
| Retrospective Studies | 19 | 2024 | 13433 | 0.400 |
Why?
| Blood | 2 | 2009 | 100 | 0.390 |
Why?
| Nucleosides | 1 | 2010 | 26 | 0.390 |
Why?
| Antitubercular Agents | 3 | 2023 | 167 | 0.390 |
Why?
| Streptococcus pneumoniae | 2 | 2022 | 144 | 0.380 |
Why?
| Programmed Cell Death 1 Receptor | 3 | 2020 | 201 | 0.370 |
Why?
| Immunoglobulin A | 4 | 2017 | 179 | 0.370 |
Why?
| Drug Therapy, Combination | 5 | 2019 | 988 | 0.370 |
Why?
| Antidepressive Agents | 3 | 2021 | 194 | 0.370 |
Why?
| Glycoproteins | 2 | 2023 | 323 | 0.370 |
Why?
| Cytosine | 3 | 2008 | 46 | 0.370 |
Why?
| Nucleotides | 1 | 2010 | 114 | 0.370 |
Why?
| Adaptive Immunity | 2 | 2017 | 165 | 0.360 |
Why?
| Membrane Glycoproteins | 4 | 2001 | 462 | 0.360 |
Why?
| Refrigeration | 1 | 2009 | 11 | 0.360 |
Why?
| Astrocytes | 1 | 2011 | 176 | 0.360 |
Why?
| Immunity, Humoral | 2 | 2021 | 116 | 0.350 |
Why?
| Enzyme-Linked Immunosorbent Assay | 8 | 2021 | 839 | 0.350 |
Why?
| Organophosphonates | 3 | 2008 | 96 | 0.350 |
Why?
| Cytomegalovirus Retinitis | 2 | 2013 | 13 | 0.350 |
Why?
| T-Lymphocytes, Helper-Inducer | 5 | 1994 | 133 | 0.340 |
Why?
| Freezing | 1 | 2009 | 85 | 0.340 |
Why?
| Tetanus | 2 | 2009 | 26 | 0.340 |
Why?
| Glioblastoma | 1 | 2011 | 262 | 0.330 |
Why?
| Benzoxazines | 3 | 2023 | 28 | 0.330 |
Why?
| Lopinavir | 3 | 2023 | 30 | 0.330 |
Why?
| Longitudinal Studies | 8 | 2019 | 2599 | 0.330 |
Why?
| Interleukin-10 | 3 | 2022 | 314 | 0.320 |
Why?
| Time Factors | 18 | 2017 | 6682 | 0.320 |
Why?
| Immunogenicity, Vaccine | 4 | 2021 | 26 | 0.320 |
Why?
| Herpesvirus 7, Human | 2 | 2005 | 5 | 0.320 |
Why?
| Pregnant Women | 4 | 2023 | 137 | 0.320 |
Why?
| Specimen Handling | 1 | 2009 | 169 | 0.320 |
Why?
| Follow-Up Studies | 13 | 2022 | 4768 | 0.320 |
Why?
| Receptors, Antigen, T-Cell, gamma-delta | 1 | 2008 | 105 | 0.320 |
Why?
| Herpesvirus 6, Human | 2 | 2005 | 13 | 0.320 |
Why?
| Norgestrel | 1 | 2007 | 2 | 0.310 |
Why?
| Biomarkers | 7 | 2021 | 3662 | 0.310 |
Why?
| Interleukins | 2 | 2008 | 246 | 0.300 |
Why?
| Incidence | 9 | 2023 | 2527 | 0.290 |
Why?
| Antigens, CD | 5 | 2017 | 506 | 0.290 |
Why?
| Prospective Studies | 11 | 2021 | 6704 | 0.290 |
Why?
| Apoptosis | 6 | 2011 | 2532 | 0.280 |
Why?
| Coinfection | 2 | 2019 | 122 | 0.280 |
Why?
| Dexamethasone | 1 | 2007 | 323 | 0.260 |
Why?
| Ritonavir | 2 | 2016 | 72 | 0.260 |
Why?
| Virus Replication | 5 | 2017 | 409 | 0.260 |
Why?
| Receptors, OX40 | 8 | 2001 | 15 | 0.260 |
Why?
| Roseolovirus Infections | 1 | 2004 | 6 | 0.250 |
Why?
| Cell Survival | 5 | 2010 | 1075 | 0.250 |
Why?
| Autoimmune Diseases | 3 | 2014 | 408 | 0.250 |
Why?
| Paramyxoviridae | 1 | 2004 | 2 | 0.250 |
Why?
| Milk, Human | 2 | 2023 | 149 | 0.250 |
Why?
| Ganciclovir | 4 | 2008 | 46 | 0.240 |
Why?
| Papillomavirus Infections | 2 | 2018 | 267 | 0.240 |
Why?
| BCG Vaccine | 2 | 2023 | 39 | 0.240 |
Why?
| Lymphokines | 4 | 1994 | 132 | 0.240 |
Why?
| Forkhead Transcription Factors | 3 | 2011 | 188 | 0.240 |
Why?
| Estradiol | 1 | 2007 | 477 | 0.240 |
Why?
| Brazil | 2 | 2021 | 111 | 0.240 |
Why?
| Immunity, Innate | 1 | 2009 | 762 | 0.240 |
Why?
| Orthomyxoviridae Infections | 1 | 2004 | 60 | 0.240 |
Why?
| Immunity | 2 | 2020 | 130 | 0.240 |
Why?
| Abnormalities, Drug-Induced | 1 | 2023 | 12 | 0.230 |
Why?
| Myelin Basic Protein | 4 | 1998 | 45 | 0.230 |
Why?
| Maternal-Fetal Exchange | 2 | 2016 | 157 | 0.230 |
Why?
| Drug-Related Side Effects and Adverse Reactions | 2 | 2017 | 240 | 0.230 |
Why?
| Acquired Immunodeficiency Syndrome | 2 | 2023 | 222 | 0.230 |
Why?
| Diabetes Mellitus, Type 1 | 4 | 2013 | 3388 | 0.230 |
Why?
| Kaposi Varicelliform Eruption | 3 | 2011 | 36 | 0.230 |
Why?
| Adenoviridae Infections | 1 | 2023 | 15 | 0.220 |
Why?
| Transforming Growth Factor beta | 3 | 2009 | 468 | 0.220 |
Why?
| Isoxazoles | 2 | 2013 | 56 | 0.220 |
Why?
| Lamivudine | 2 | 2015 | 60 | 0.220 |
Why?
| Liver Failure, Acute | 1 | 2023 | 68 | 0.220 |
Why?
| South Africa | 6 | 2020 | 165 | 0.220 |
Why?
| Zidovudine | 2 | 2015 | 78 | 0.220 |
Why?
| HIV Integrase Inhibitors | 1 | 2023 | 61 | 0.220 |
Why?
| Herpes Genitalis | 2 | 2012 | 19 | 0.220 |
Why?
| Cyclopropanes | 2 | 2020 | 80 | 0.210 |
Why?
| Lymphocytosis | 1 | 2021 | 10 | 0.210 |
Why?
| Antibodies, Monoclonal, Murine-Derived | 2 | 2013 | 86 | 0.210 |
Why?
| Alkynes | 2 | 2020 | 56 | 0.210 |
Why?
| United States | 8 | 2023 | 13272 | 0.210 |
Why?
| Antigens, Differentiation | 1 | 2001 | 82 | 0.210 |
Why?
| Tuberculin Test | 1 | 2021 | 33 | 0.210 |
Why?
| Interferon-gamma Release Tests | 1 | 2021 | 26 | 0.210 |
Why?
| Maternal Exposure | 1 | 2023 | 148 | 0.200 |
Why?
| Atazanavir Sulfate | 2 | 2023 | 41 | 0.200 |
Why?
| Heart Transplantation | 9 | 2001 | 674 | 0.200 |
Why?
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2021 | 59 | 0.200 |
Why?
| Cells, Cultured | 11 | 2010 | 4162 | 0.190 |
Why?
| Phenotype | 6 | 2009 | 3070 | 0.190 |
Why?
| Medication Therapy Management | 1 | 2021 | 73 | 0.190 |
Why?
| Virus Activation | 3 | 2013 | 80 | 0.190 |
Why?
| Immunoglobulins | 2 | 2017 | 166 | 0.190 |
Why?
| Evolution, Molecular | 1 | 2005 | 459 | 0.190 |
Why?
| Biliary Atresia | 1 | 2023 | 226 | 0.190 |
Why?
| Risk Factors | 16 | 2020 | 9381 | 0.190 |
Why?
| North America | 2 | 2023 | 271 | 0.190 |
Why?
| Receptors, Immunologic | 2 | 2000 | 228 | 0.190 |
Why?
| HIV Seronegativity | 1 | 2020 | 25 | 0.190 |
Why?
| RNA, Ribosomal, 16S | 1 | 2022 | 535 | 0.180 |
Why?
| Inflammation | 4 | 2019 | 2598 | 0.180 |
Why?
| Heart-Assist Devices | 8 | 2000 | 487 | 0.180 |
Why?
| T-Cell Antigen Receptor Specificity | 1 | 2019 | 41 | 0.180 |
Why?
| Interleukin-2 Receptor alpha Subunit | 1 | 2019 | 70 | 0.180 |
Why?
| Treatment Outcome | 14 | 2017 | 9692 | 0.180 |
Why?
| Neurodevelopmental Disorders | 1 | 2021 | 122 | 0.180 |
Why?
| Eicosanoids | 1 | 2019 | 55 | 0.180 |
Why?
| Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 | 2 | 2017 | 15 | 0.180 |
Why?
| Abatacept | 2 | 2013 | 43 | 0.170 |
Why?
| Survival Analysis | 6 | 2018 | 1325 | 0.170 |
Why?
| Dose-Response Relationship, Immunologic | 2 | 2016 | 87 | 0.170 |
Why?
| Cholera Toxin | 1 | 2018 | 28 | 0.170 |
Why?
| Depressive Disorder, Major | 2 | 2013 | 309 | 0.170 |
Why?
| Saliva | 2 | 2010 | 215 | 0.170 |
Why?
| Hospitals | 1 | 2023 | 633 | 0.160 |
Why?
| Fatty Acid-Binding Proteins | 1 | 2018 | 61 | 0.160 |
Why?
| RNA, Messenger | 8 | 2011 | 2720 | 0.160 |
Why?
| Delayed-Action Preparations | 2 | 2016 | 162 | 0.160 |
Why?
| Latin America | 1 | 2018 | 77 | 0.160 |
Why?
| Vaccination Coverage | 1 | 2018 | 66 | 0.160 |
Why?
| Postoperative Complications | 13 | 2001 | 2301 | 0.160 |
Why?
| Cell Movement | 2 | 2001 | 929 | 0.160 |
Why?
| Coronary Artery Bypass | 4 | 2001 | 226 | 0.160 |
Why?
| Lysosomal-Associated Membrane Protein 1 | 1 | 2017 | 5 | 0.160 |
Why?
| CD4-CD8 Ratio | 2 | 2008 | 20 | 0.160 |
Why?
| Injections, Intradermal | 1 | 2017 | 11 | 0.150 |
Why?
| Injections, Subcutaneous | 2 | 2016 | 137 | 0.150 |
Why?
| Sensitivity and Specificity | 4 | 2009 | 1855 | 0.150 |
Why?
| Placenta | 2 | 2021 | 648 | 0.150 |
Why?
| Paralysis | 1 | 2017 | 68 | 0.150 |
Why?
| Nervous System Diseases | 1 | 2020 | 265 | 0.150 |
Why?
| Seroconversion | 1 | 2017 | 46 | 0.150 |
Why?
| Africa | 1 | 2017 | 102 | 0.150 |
Why?
| Arm | 1 | 2017 | 107 | 0.150 |
Why?
| Seizures | 1 | 2020 | 360 | 0.150 |
Why?
| Genotype | 5 | 2020 | 1943 | 0.150 |
Why?
| Nelfinavir | 1 | 2016 | 8 | 0.140 |
Why?
| Kinetics | 3 | 2010 | 1658 | 0.140 |
Why?
| Clinical Trials as Topic | 2 | 2019 | 985 | 0.140 |
Why?
| Adoptive Transfer | 3 | 2002 | 214 | 0.140 |
Why?
| Aging | 3 | 2017 | 1694 | 0.140 |
Why?
| Cross Reactions | 2 | 2014 | 118 | 0.140 |
Why?
| Monocytes | 1 | 2019 | 523 | 0.140 |
Why?
| Colorado | 2 | 2023 | 4325 | 0.140 |
Why?
| RNA | 1 | 2022 | 854 | 0.140 |
Why?
| Animals | 20 | 2011 | 34133 | 0.140 |
Why?
| Demography | 2 | 2018 | 290 | 0.140 |
Why?
| Nevirapine | 1 | 2015 | 14 | 0.130 |
Why?
| Comorbidity | 2 | 2019 | 1600 | 0.130 |
Why?
| Contraceptives, Oral, Synthetic | 1 | 2015 | 2 | 0.130 |
Why?
| Nasopharynx | 1 | 2015 | 66 | 0.130 |
Why?
| Virus Cultivation | 2 | 2005 | 25 | 0.130 |
Why?
| Nasal Lavage Fluid | 2 | 2005 | 11 | 0.130 |
Why?
| Computational Biology | 1 | 2019 | 601 | 0.130 |
Why?
| Liver Transplantation | 1 | 2023 | 929 | 0.130 |
Why?
| Transcription, Genetic | 1 | 2021 | 1355 | 0.130 |
Why?
| Neutropenia | 1 | 2015 | 134 | 0.130 |
Why?
| Infant, Newborn, Diseases | 1 | 2016 | 108 | 0.120 |
Why?
| Virus Latency | 2 | 2013 | 80 | 0.120 |
Why?
| Antigens, Differentiation, T-Lymphocyte | 1 | 1994 | 87 | 0.120 |
Why?
| Feces | 1 | 2017 | 410 | 0.120 |
Why?
| Pandemics | 2 | 2021 | 1401 | 0.120 |
Why?
| Killer Cells, Natural | 2 | 2009 | 386 | 0.120 |
Why?
| Physical Fitness | 1 | 2015 | 184 | 0.120 |
Why?
| Anemia | 1 | 2015 | 156 | 0.120 |
Why?
| Drug Resistance, Multiple, Viral | 1 | 2013 | 11 | 0.120 |
Why?
| Skin Diseases | 1 | 2016 | 171 | 0.120 |
Why?
| Herpesvirus 8, Human | 2 | 2005 | 69 | 0.120 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2017 | 1003 | 0.120 |
Why?
| Progesterone | 2 | 2015 | 243 | 0.120 |
Why?
| Transcriptome | 1 | 2019 | 774 | 0.120 |
Why?
| Base Sequence | 5 | 2017 | 2186 | 0.120 |
Why?
| Multivariate Analysis | 4 | 2017 | 1531 | 0.110 |
Why?
| Depression | 1 | 2021 | 1190 | 0.110 |
Why?
| Thrombocytopenia | 1 | 2015 | 188 | 0.110 |
Why?
| Leukocyte Common Antigens | 2 | 2009 | 84 | 0.110 |
Why?
| Lung Transplantation | 3 | 2001 | 273 | 0.110 |
Why?
| Tumor Virus Infections | 1 | 2013 | 41 | 0.110 |
Why?
| Polyomavirus Infections | 1 | 2013 | 24 | 0.110 |
Why?
| Epitopes | 2 | 2009 | 450 | 0.110 |
Why?
| Epitopes, T-Lymphocyte | 1 | 2014 | 170 | 0.110 |
Why?
| Mothers | 1 | 2019 | 728 | 0.110 |
Why?
| Graft Rejection | 4 | 2001 | 556 | 0.110 |
Why?
| OX40 Ligand | 4 | 2001 | 10 | 0.110 |
Why?
| Proctitis | 1 | 2012 | 4 | 0.110 |
Why?
| Communicable Diseases | 1 | 2014 | 135 | 0.110 |
Why?
| Oxidative Stress | 1 | 2019 | 1204 | 0.110 |
Why?
| Oxadiazoles | 1 | 2012 | 33 | 0.110 |
Why?
| Mycophenolic Acid | 1 | 2012 | 80 | 0.110 |
Why?
| Rats, Inbred Lew | 4 | 1998 | 87 | 0.110 |
Why?
| Aprotinin | 3 | 1997 | 9 | 0.110 |
Why?
| Interferon Regulatory Factor-2 | 1 | 2011 | 5 | 0.110 |
Why?
| DNA Primase | 1 | 2012 | 43 | 0.110 |
Why?
| HIV Seropositivity | 1 | 2013 | 117 | 0.110 |
Why?
| Cell Line | 3 | 2009 | 2785 | 0.100 |
Why?
| Fluorescent Antibody Technique, Direct | 1 | 2011 | 10 | 0.100 |
Why?
| L-Selectin | 2 | 2009 | 27 | 0.100 |
Why?
| Length of Stay | 3 | 2014 | 1077 | 0.100 |
Why?
| Histocompatibility Testing | 3 | 2001 | 123 | 0.100 |
Why?
| CD8 Antigens | 1 | 2011 | 75 | 0.100 |
Why?
| Coculture Techniques | 1 | 2011 | 213 | 0.100 |
Why?
| DNA Helicases | 1 | 2012 | 136 | 0.100 |
Why?
| Immunization Schedule | 3 | 2020 | 187 | 0.100 |
Why?
| Ribavirin | 1 | 2011 | 89 | 0.100 |
Why?
| Fetal Blood | 2 | 2019 | 275 | 0.100 |
Why?
| Predictive Value of Tests | 3 | 2005 | 1947 | 0.090 |
Why?
| Parturition | 1 | 2011 | 58 | 0.090 |
Why?
| Fluorescent Antibody Technique | 2 | 2016 | 420 | 0.090 |
Why?
| Menstrual Cycle | 1 | 2011 | 115 | 0.090 |
Why?
| Motor Activity | 1 | 2015 | 679 | 0.090 |
Why?
| Herpesvirus Vaccines | 1 | 2010 | 4 | 0.090 |
Why?
| Logistic Models | 5 | 2010 | 1995 | 0.090 |
Why?
| Algorithms | 3 | 2021 | 1593 | 0.090 |
Why?
| Granzymes | 1 | 2009 | 40 | 0.090 |
Why?
| Herpes Simplex Virus Vaccines | 1 | 2009 | 3 | 0.090 |
Why?
| Pokeweed Mitogens | 1 | 2009 | 6 | 0.090 |
Why?
| Viral Plaque Assay | 2 | 2006 | 25 | 0.090 |
Why?
| Human Experimentation | 1 | 2009 | 16 | 0.090 |
Why?
| Neuralgia, Postherpetic | 1 | 2009 | 43 | 0.090 |
Why?
| Immune System | 2 | 2008 | 184 | 0.090 |
Why?
| Immunologic Factors | 1 | 2011 | 228 | 0.090 |
Why?
| Drug Stability | 1 | 2009 | 157 | 0.090 |
Why?
| Guanine | 2 | 2006 | 76 | 0.090 |
Why?
| Cost of Illness | 1 | 2011 | 284 | 0.090 |
Why?
| Gene Rearrangement, T-Lymphocyte | 1 | 2008 | 13 | 0.090 |
Why?
| Nasal Mucosa | 1 | 2009 | 97 | 0.090 |
Why?
| Infant Mortality | 2 | 2019 | 96 | 0.080 |
Why?
| Apoptosis Regulatory Proteins | 1 | 2009 | 198 | 0.080 |
Why?
| Tumor Necrosis Factor-alpha | 1 | 2014 | 1181 | 0.080 |
Why?
| Sarcoma | 1 | 2010 | 138 | 0.080 |
Why?
| Botswana | 2 | 2019 | 8 | 0.080 |
Why?
| Cyclosporine | 2 | 2001 | 175 | 0.080 |
Why?
| Betaherpesvirinae | 1 | 2008 | 1 | 0.080 |
Why?
| Inflammation Mediators | 1 | 2011 | 515 | 0.080 |
Why?
| Administration, Intranasal | 1 | 2008 | 74 | 0.080 |
Why?
| Exodeoxyribonucleases | 1 | 2008 | 22 | 0.080 |
Why?
| Enzyme Inhibitors | 1 | 2012 | 836 | 0.080 |
Why?
| Antibodies, Monoclonal, Humanized | 1 | 2012 | 658 | 0.080 |
Why?
| Genetic Variation | 2 | 2011 | 952 | 0.080 |
Why?
| Interleukin-15 | 1 | 2008 | 77 | 0.080 |
Why?
| Mice | 11 | 2011 | 15888 | 0.080 |
Why?
| Veterans | 1 | 2018 | 1203 | 0.080 |
Why?
| Interleukin-12 | 1 | 2008 | 111 | 0.080 |
Why?
| Trypan Blue | 1 | 2007 | 4 | 0.080 |
Why?
| Didanosine | 1 | 2007 | 14 | 0.080 |
Why?
| Rats | 5 | 1998 | 5426 | 0.080 |
Why?
| Thymus Gland | 1 | 2008 | 308 | 0.080 |
Why?
| Randomized Controlled Trials as Topic | 2 | 2011 | 1260 | 0.080 |
Why?
| Multicenter Studies as Topic | 2 | 2006 | 247 | 0.080 |
Why?
| Pneumonia | 1 | 2013 | 605 | 0.080 |
Why?
| Data Interpretation, Statistical | 1 | 2009 | 345 | 0.070 |
Why?
| Quality Control | 1 | 2007 | 165 | 0.070 |
Why?
| Gene Expression | 3 | 2006 | 1506 | 0.070 |
Why?
| Vero Cells | 1 | 2006 | 69 | 0.070 |
Why?
| Inhibitory Concentration 50 | 1 | 2006 | 82 | 0.070 |
Why?
| Cerebrospinal Fluid | 2 | 2004 | 92 | 0.070 |
Why?
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2010 | 268 | 0.070 |
Why?
| In Vitro Techniques | 3 | 2006 | 1130 | 0.070 |
Why?
| Drug Interactions | 2 | 2020 | 356 | 0.070 |
Why?
| Nucleic Acid Hybridization | 1 | 2006 | 193 | 0.070 |
Why?
| Deoxycytidine | 1 | 2007 | 141 | 0.070 |
Why?
| Immunoenzyme Techniques | 1 | 2006 | 201 | 0.070 |
Why?
| Disease Models, Animal | 2 | 2011 | 3799 | 0.070 |
Why?
| Opportunistic Infections | 2 | 2014 | 45 | 0.070 |
Why?
| Hemostatics | 2 | 1997 | 50 | 0.070 |
Why?
| Immunotherapy, Adoptive | 2 | 2001 | 192 | 0.070 |
Why?
| Hemadsorption | 1 | 2005 | 1 | 0.070 |
Why?
| Cytopathogenic Effect, Viral | 1 | 2005 | 18 | 0.070 |
Why?
| Tumor Necrosis Factors | 3 | 2001 | 9 | 0.070 |
Why?
| Risk Assessment | 2 | 2014 | 3213 | 0.070 |
Why?
| Protein Structure, Tertiary | 1 | 2008 | 832 | 0.070 |
Why?
| Signal Transduction | 2 | 2000 | 4902 | 0.070 |
Why?
| Evaluation Studies as Topic | 1 | 2005 | 190 | 0.070 |
Why?
| Gene Products, pol | 1 | 2005 | 6 | 0.070 |
Why?
| Transforming Growth Factor beta1 | 1 | 2006 | 169 | 0.070 |
Why?
| Clinical Trials, Phase II as Topic | 2 | 2017 | 58 | 0.070 |
Why?
| Annexin A5 | 1 | 2004 | 25 | 0.070 |
Why?
| Cysteine Proteinase Inhibitors | 1 | 2004 | 51 | 0.060 |
Why?
| Antigens | 2 | 2008 | 337 | 0.060 |
Why?
| Emtricitabine | 2 | 2021 | 147 | 0.060 |
Why?
| Meningitis, Viral | 1 | 2004 | 21 | 0.060 |
Why?
| Parainfluenza Virus 1, Human | 1 | 2004 | 2 | 0.060 |
Why?
| Parainfluenza Virus 2, Human | 1 | 2004 | 3 | 0.060 |
Why?
| Parainfluenza Virus 3, Human | 1 | 2004 | 5 | 0.060 |
Why?
| Seroepidemiologic Studies | 1 | 2005 | 147 | 0.060 |
Why?
| Disease Transmission, Infectious | 1 | 2005 | 59 | 0.060 |
Why?
| Adenoviruses, Human | 1 | 2004 | 25 | 0.060 |
Why?
| Sarcoma, Kaposi | 2 | 2003 | 73 | 0.060 |
Why?
| Cell Culture Techniques | 1 | 2006 | 354 | 0.060 |
Why?
| Bone Marrow Transplantation | 1 | 2005 | 253 | 0.060 |
Why?
| Cell Line, Tumor | 1 | 2011 | 2904 | 0.060 |
Why?
| Fatal Outcome | 1 | 2005 | 299 | 0.060 |
Why?
| Fibroblasts | 2 | 2006 | 846 | 0.060 |
Why?
| Chlamydophila Infections | 1 | 2003 | 4 | 0.060 |
Why?
| Leukemia, Myeloid, Acute | 1 | 2010 | 534 | 0.060 |
Why?
| Chlamydophila pneumoniae | 1 | 2003 | 11 | 0.060 |
Why?
| Rilpivirine | 1 | 2023 | 3 | 0.060 |
Why?
| HLA-DR Antigens | 3 | 2001 | 228 | 0.060 |
Why?
| Hospital Mortality | 4 | 2001 | 901 | 0.060 |
Why?
| Arteriosclerosis | 1 | 2003 | 90 | 0.060 |
Why?
| Darunavir | 1 | 2023 | 18 | 0.060 |
Why?
| Herpes Labialis | 1 | 2003 | 9 | 0.060 |
Why?
| Bronchiolitis Obliterans | 2 | 2001 | 69 | 0.060 |
Why?
| Portoenterostomy, Hepatic | 1 | 2023 | 64 | 0.060 |
Why?
| Pregnancy Trimester, First | 1 | 2023 | 128 | 0.060 |
Why?
| Receptors, Antigen, T-Cell, alpha-beta | 2 | 1994 | 314 | 0.060 |
Why?
| DNA Primers | 3 | 2009 | 540 | 0.050 |
Why?
| Bronchoalveolar Lavage Fluid | 1 | 2005 | 633 | 0.050 |
Why?
| Adenoviridae | 1 | 2023 | 195 | 0.050 |
Why?
| Zimbabwe | 2 | 2017 | 45 | 0.050 |
Why?
| Microbial Sensitivity Tests | 1 | 2003 | 312 | 0.050 |
Why?
| Risk | 1 | 2005 | 890 | 0.050 |
Why?
| Glioma | 1 | 2005 | 300 | 0.050 |
Why?
| Ovalbumin | 1 | 2001 | 170 | 0.050 |
Why?
| CTLA-4 Antigen | 1 | 2001 | 86 | 0.050 |
Why?
| Receptors, CXCR5 | 1 | 2021 | 11 | 0.050 |
Why?
| Cobicistat | 1 | 2021 | 5 | 0.050 |
Why?
| B7-1 Antigen | 2 | 1998 | 70 | 0.050 |
Why?
| Antibody Affinity | 1 | 2021 | 55 | 0.050 |
Why?
| Rituximab | 2 | 2013 | 161 | 0.050 |
Why?
| Vaccines, Subunit | 1 | 2021 | 44 | 0.050 |
Why?
| Equivalence Trials as Topic | 1 | 2020 | 6 | 0.050 |
Why?
| Arylamine N-Acetyltransferase | 1 | 2020 | 5 | 0.050 |
Why?
| Cytochrome P-450 CYP2B6 | 1 | 2020 | 9 | 0.050 |
Why?
| Models, Statistical | 1 | 2005 | 651 | 0.050 |
Why?
| Prostheses and Implants | 3 | 1996 | 145 | 0.050 |
Why?
| Immunoglobulins, Intravenous | 1 | 2002 | 130 | 0.050 |
Why?
| Alanine | 1 | 2021 | 103 | 0.050 |
Why?
| Pre-Eclampsia | 1 | 2023 | 187 | 0.050 |
Why?
| Metabolic Clearance Rate | 1 | 2020 | 111 | 0.050 |
Why?
| Sentinel Lymph Node Biopsy | 1 | 2001 | 118 | 0.050 |
Why?
| Spinal Cord | 2 | 1994 | 364 | 0.050 |
Why?
| Lymphatic Metastasis | 1 | 2001 | 310 | 0.050 |
Why?
| Heart Failure | 3 | 1999 | 2114 | 0.050 |
Why?
| DNA | 2 | 2006 | 1401 | 0.050 |
Why?
| Living Donors | 1 | 2023 | 322 | 0.050 |
Why?
| Cancer Vaccines | 1 | 2001 | 141 | 0.050 |
Why?
| Confusion | 1 | 2020 | 27 | 0.050 |
Why?
| Hemodynamics | 3 | 2001 | 1036 | 0.050 |
Why?
| Survival Rate | 6 | 2000 | 1810 | 0.040 |
Why?
| Encephalitis, Viral | 1 | 2020 | 44 | 0.040 |
Why?
| Neoplasms | 3 | 2001 | 2235 | 0.040 |
Why?
| Tenofovir | 1 | 2021 | 211 | 0.040 |
Why?
| California | 2 | 2015 | 387 | 0.040 |
Why?
| Coronary Disease | 2 | 2001 | 372 | 0.040 |
Why?
| Candidiasis | 1 | 1999 | 59 | 0.040 |
Why?
| Antibodies | 1 | 2001 | 400 | 0.040 |
Why?
| Triiodothyronine | 1 | 1999 | 45 | 0.040 |
Why?
| Liver Function Tests | 1 | 2019 | 114 | 0.040 |
Why?
| Hemagglutination | 1 | 2018 | 7 | 0.040 |
Why?
| Infant, Very Low Birth Weight | 1 | 2019 | 71 | 0.040 |
Why?
| Macrophage-1 Antigen | 1 | 1999 | 36 | 0.040 |
Why?
| Adenine | 1 | 2021 | 227 | 0.040 |
Why?
| Acetates | 1 | 2019 | 100 | 0.040 |
Why?
| Recombinant Fusion Proteins | 2 | 1999 | 661 | 0.040 |
Why?
| Arginine Vasopressin | 1 | 1998 | 47 | 0.040 |
Why?
| Hypoplastic Left Heart Syndrome | 1 | 2000 | 113 | 0.040 |
Why?
| Mice, Inbred BALB C | 1 | 2001 | 1245 | 0.040 |
Why?
| Haptoglobins | 1 | 2018 | 30 | 0.040 |
Why?
| Polymorphism, Single Nucleotide | 3 | 2011 | 2127 | 0.040 |
Why?
| Brain Diseases | 1 | 2020 | 141 | 0.040 |
Why?
| HLA-B Antigens | 1 | 1998 | 55 | 0.040 |
Why?
| Vasoconstrictor Agents | 1 | 1998 | 128 | 0.040 |
Why?
| Delivery, Obstetric | 1 | 2019 | 134 | 0.040 |
Why?
| Quinazolines | 1 | 2019 | 243 | 0.040 |
Why?
| Antibody Specificity | 1 | 1998 | 190 | 0.040 |
Why?
| Clinical Trials, Phase I as Topic | 1 | 2017 | 50 | 0.040 |
Why?
| Protein Precursors | 1 | 2018 | 126 | 0.040 |
Why?
| Sterols | 1 | 2017 | 17 | 0.040 |
Why?
| Inositol Phosphates | 1 | 2017 | 28 | 0.040 |
Why?
| Interleukin-3 | 2 | 1994 | 27 | 0.040 |
Why?
| Proviruses | 1 | 2017 | 9 | 0.040 |
Why?
| Autogenic Training | 1 | 1997 | 1 | 0.040 |
Why?
| Shock | 1 | 1998 | 96 | 0.040 |
Why?
| Observational Studies as Topic | 1 | 2017 | 91 | 0.040 |
Why?
| Radioactive Fallout | 1 | 1997 | 2 | 0.040 |
Why?
| Leukemia, Radiation-Induced | 1 | 1997 | 4 | 0.040 |
Why?
| Radioactive Hazard Release | 1 | 1997 | 2 | 0.040 |
Why?
| Relaxation Therapy | 1 | 1997 | 13 | 0.040 |
Why?
| Reproducibility of Results | 1 | 2005 | 2977 | 0.040 |
Why?
| Tanzania | 1 | 2017 | 47 | 0.040 |
Why?
| Product Surveillance, Postmarketing | 1 | 2017 | 70 | 0.040 |
Why?
| Sequence Analysis | 1 | 2017 | 39 | 0.040 |
Why?
| Power Plants | 1 | 1997 | 7 | 0.040 |
Why?
| Lung Injury | 1 | 2000 | 215 | 0.040 |
Why?
| Immunization | 1 | 2020 | 421 | 0.040 |
Why?
| Zambia | 1 | 2017 | 69 | 0.040 |
Why?
| Encephalitis | 1 | 1998 | 128 | 0.040 |
Why?
| Ligands | 1 | 1999 | 582 | 0.040 |
Why?
| Plasma | 1 | 2018 | 223 | 0.040 |
Why?
| Prevalence | 2 | 2018 | 2442 | 0.040 |
Why?
| Heart Valves | 1 | 1997 | 46 | 0.040 |
Why?
| Neoplasms, Radiation-Induced | 1 | 1997 | 73 | 0.040 |
Why?
| Hemagglutinin Glycoproteins, Influenza Virus | 1 | 2016 | 22 | 0.040 |
Why?
| Aortic Valve Insufficiency | 1 | 1996 | 45 | 0.040 |
Why?
| Erythema | 1 | 2016 | 26 | 0.040 |
Why?
| Body Weight | 1 | 2020 | 958 | 0.030 |
Why?
| Heart Arrest, Induced | 1 | 1995 | 32 | 0.030 |
Why?
| Thromboembolism | 1 | 1996 | 105 | 0.030 |
Why?
| Up-Regulation | 2 | 2001 | 891 | 0.030 |
Why?
| Blood Transfusion | 2 | 1995 | 312 | 0.030 |
Why?
| Graft vs Host Disease | 1 | 1998 | 219 | 0.030 |
Why?
| Gene Regulatory Networks | 1 | 2017 | 244 | 0.030 |
Why?
| Antibodies, Monoclonal | 2 | 2001 | 1306 | 0.030 |
Why?
| Vasodilation | 1 | 1998 | 462 | 0.030 |
Why?
| Chi-Square Distribution | 2 | 2013 | 551 | 0.030 |
Why?
| Registries | 1 | 2024 | 2020 | 0.030 |
Why?
| Hematologic Neoplasms | 1 | 1997 | 135 | 0.030 |
Why?
| Reference Values | 2 | 2011 | 789 | 0.030 |
Why?
| Intestines | 1 | 2018 | 338 | 0.030 |
Why?
| Ovulation | 1 | 2015 | 41 | 0.030 |
Why?
| Cross Infection | 1 | 1997 | 218 | 0.030 |
Why?
| Molecular Sequence Data | 3 | 1994 | 2933 | 0.030 |
Why?
| Liver | 1 | 2023 | 1827 | 0.030 |
Why?
| Hypothermia, Induced | 1 | 1995 | 69 | 0.030 |
Why?
| Quality of Life | 4 | 2000 | 2457 | 0.030 |
Why?
| Surgical Wound Infection | 1 | 1997 | 251 | 0.030 |
Why?
| Blood Loss, Surgical | 1 | 1995 | 89 | 0.030 |
Why?
| Rats, Inbred BUF | 1 | 1994 | 1 | 0.030 |
Why?
| HLA-A2 Antigen | 1 | 2014 | 39 | 0.030 |
Why?
| Cardiac Surgical Procedures | 1 | 1998 | 477 | 0.030 |
Why?
| Polymorphism, Restriction Fragment Length | 2 | 2003 | 64 | 0.030 |
Why?
| Colony-Stimulating Factors | 2 | 1990 | 32 | 0.030 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2001 | 1402 | 0.030 |
Why?
| Brain Neoplasms | 1 | 2001 | 1016 | 0.030 |
Why?
| Cause of Death | 3 | 2001 | 389 | 0.030 |
Why?
| Myocardial Infarction | 1 | 2001 | 1134 | 0.030 |
Why?
| BK Virus | 1 | 2013 | 15 | 0.030 |
Why?
| Growth Substances | 2 | 1990 | 140 | 0.030 |
Why?
| JC Virus | 1 | 2013 | 23 | 0.030 |
Why?
| Pulmonary Emphysema | 1 | 1996 | 342 | 0.030 |
Why?
| Herpesviridae | 1 | 2012 | 21 | 0.030 |
Why?
| Granulocyte-Macrophage Colony-Stimulating Factor | 2 | 1990 | 153 | 0.030 |
Why?
| Ambulatory Care | 1 | 1996 | 497 | 0.030 |
Why?
| Hypersensitivity, Delayed | 1 | 1992 | 52 | 0.030 |
Why?
| Genetic Predisposition to Disease | 2 | 2011 | 2359 | 0.030 |
Why?
| Ventricular Function, Left | 1 | 1995 | 493 | 0.030 |
Why?
| Metabolomics | 1 | 2017 | 550 | 0.030 |
Why?
| Sex Characteristics | 1 | 2017 | 690 | 0.030 |
Why?
| Aortic Valve | 1 | 1996 | 428 | 0.030 |
Why?
| Spleen | 1 | 1994 | 543 | 0.030 |
Why?
| Heart Diseases | 1 | 1995 | 358 | 0.030 |
Why?
| Kaplan-Meier Estimate | 1 | 2014 | 884 | 0.030 |
Why?
| Patient Selection | 1 | 1995 | 717 | 0.030 |
Why?
| Histocompatibility Antigens | 1 | 1992 | 105 | 0.030 |
Why?
| Kidney Failure, Chronic | 1 | 1997 | 519 | 0.020 |
Why?
| Matched-Pair Analysis | 1 | 2011 | 42 | 0.020 |
Why?
| Receptors, Interferon | 1 | 2011 | 50 | 0.020 |
Why?
| Lung Neoplasms | 2 | 2001 | 2216 | 0.020 |
Why?
| Age of Onset | 1 | 2012 | 479 | 0.020 |
Why?
| Administration, Oral | 1 | 2013 | 786 | 0.020 |
Why?
| Stroke | 1 | 2000 | 1090 | 0.020 |
Why?
| Infant, Premature | 1 | 2014 | 507 | 0.020 |
Why?
| Radiotherapy | 2 | 2005 | 187 | 0.020 |
Why?
| Cell Separation | 1 | 2011 | 303 | 0.020 |
Why?
| Concanavalin A | 1 | 1990 | 76 | 0.020 |
Why?
| Anxiety | 1 | 1997 | 888 | 0.020 |
Why?
| Papillomaviridae | 1 | 2010 | 102 | 0.020 |
Why?
| Mice, Knockout | 2 | 2011 | 2737 | 0.020 |
Why?
| Blotting, Northern | 1 | 1990 | 199 | 0.020 |
Why?
| Tetradecanoylphorbol Acetate | 1 | 1990 | 162 | 0.020 |
Why?
| Haplotypes | 1 | 2011 | 482 | 0.020 |
Why?
| Prenatal Exposure Delayed Effects | 1 | 2016 | 511 | 0.020 |
Why?
| Genetic Association Studies | 1 | 2011 | 383 | 0.020 |
Why?
| Herpesvirus 1, Bovine | 1 | 1989 | 2 | 0.020 |
Why?
| beta-Globins | 1 | 2009 | 16 | 0.020 |
Why?
| Practice Guidelines as Topic | 1 | 2017 | 1519 | 0.020 |
Why?
| Arthritis, Rheumatoid | 1 | 1998 | 985 | 0.020 |
Why?
| Mice, Inbred Strains | 1 | 1990 | 418 | 0.020 |
Why?
| Phylogeny | 1 | 2013 | 830 | 0.020 |
Why?
| Immunoglobulin E | 1 | 2010 | 368 | 0.020 |
Why?
| Reference Standards | 1 | 2009 | 177 | 0.020 |
Why?
| Multiple Sclerosis | 1 | 1994 | 395 | 0.020 |
Why?
| Oligonucleotide Array Sequence Analysis | 1 | 2011 | 783 | 0.020 |
Why?
| Infusions, Intravenous | 2 | 1999 | 396 | 0.020 |
Why?
| Linear Models | 1 | 2010 | 854 | 0.020 |
Why?
| Membrane Proteins | 1 | 1994 | 1093 | 0.020 |
Why?
| Analysis of Variance | 1 | 2011 | 1329 | 0.020 |
Why?
| Time | 1 | 2007 | 81 | 0.020 |
Why?
| Drug Resistance, Multiple | 1 | 2006 | 19 | 0.020 |
Why?
| Kidney Transplantation | 1 | 2013 | 584 | 0.020 |
Why?
| Antineoplastic Agents | 2 | 2010 | 1990 | 0.020 |
Why?
| Postoperative Care | 2 | 1999 | 245 | 0.020 |
Why?
| Clinical Protocols | 1 | 2007 | 248 | 0.020 |
Why?
| Templates, Genetic | 1 | 2005 | 59 | 0.020 |
Why?
| Hematopoietic Stem Cells | 1 | 1988 | 370 | 0.020 |
Why?
| Interleukin-5 | 2 | 1998 | 32 | 0.020 |
Why?
| Codon | 1 | 2005 | 90 | 0.020 |
Why?
| Drug Administration Schedule | 1 | 2007 | 757 | 0.020 |
Why?
| DNA Replication | 1 | 2006 | 214 | 0.020 |
Why?
| Diagnosis, Differential | 1 | 2009 | 1423 | 0.020 |
Why?
| Age Distribution | 1 | 2005 | 376 | 0.020 |
Why?
| Mice, Transgenic | 2 | 2000 | 2079 | 0.020 |
Why?
| Sex Distribution | 1 | 2005 | 370 | 0.020 |
Why?
| Creatinine | 2 | 1997 | 510 | 0.020 |
Why?
| Vaccines | 1 | 2009 | 384 | 0.020 |
Why?
| Abdominal Neoplasms | 1 | 2003 | 28 | 0.010 |
Why?
| Lung | 1 | 1996 | 3830 | 0.010 |
Why?
| Disease Progression | 1 | 2010 | 2546 | 0.010 |
Why?
| Endemic Diseases | 1 | 2003 | 29 | 0.010 |
Why?
| Neuroblastoma | 1 | 2003 | 137 | 0.010 |
Why?
| Cell Differentiation | 3 | 2000 | 1805 | 0.010 |
Why?
| Sequence Analysis, DNA | 1 | 2005 | 766 | 0.010 |
Why?
| Peptide Fragments | 2 | 1998 | 715 | 0.010 |
Why?
| Fibrosarcoma | 1 | 2001 | 20 | 0.010 |
Why?
| Anticoagulants | 2 | 1996 | 589 | 0.010 |
Why?
| Injections, Intravenous | 1 | 2001 | 217 | 0.010 |
Why?
| Mice, Inbred C57BL | 2 | 2001 | 5020 | 0.010 |
Why?
| HLA-A Antigens | 1 | 2001 | 52 | 0.010 |
Why?
| Lymphocytes, Tumor-Infiltrating | 1 | 2001 | 115 | 0.010 |
Why?
| Myocardial Revascularization | 1 | 2001 | 84 | 0.010 |
Why?
| Immune Sera | 1 | 2000 | 83 | 0.010 |
Why?
| Muscle, Smooth, Vascular | 1 | 2003 | 454 | 0.010 |
Why?
| Melanoma, Experimental | 1 | 2001 | 116 | 0.010 |
Why?
| Clone Cells | 1 | 2000 | 255 | 0.010 |
Why?
| Probability | 1 | 2001 | 316 | 0.010 |
Why?
| Cross-Sectional Studies | 1 | 2011 | 4734 | 0.010 |
Why?
| Amino Acid Sequence | 2 | 1994 | 2123 | 0.010 |
Why?
| Students | 1 | 2005 | 529 | 0.010 |
Why?
| Databases as Topic | 1 | 2000 | 79 | 0.010 |
Why?
| Emergency Treatment | 1 | 2001 | 117 | 0.010 |
Why?
| New York | 1 | 2000 | 121 | 0.010 |
Why?
| Carotid Artery Diseases | 1 | 2000 | 61 | 0.010 |
Why?
| Cytochrome c Group | 1 | 1998 | 37 | 0.010 |
Why?
| Columbidae | 1 | 1998 | 32 | 0.010 |
Why?
| Peripheral Vascular Diseases | 1 | 2000 | 102 | 0.010 |
Why?
| Prognosis | 2 | 1998 | 3563 | 0.010 |
Why?
| Cardiac Output | 1 | 1999 | 154 | 0.010 |
Why?
| Lymph Nodes | 1 | 2001 | 466 | 0.010 |
Why?
| Life Tables | 1 | 1998 | 19 | 0.010 |
Why?
| Endocardium | 1 | 1998 | 33 | 0.010 |
Why?
| Aortic Diseases | 1 | 2000 | 95 | 0.010 |
Why?
| Cardiotonic Agents | 1 | 1999 | 133 | 0.010 |
Why?
| Cell Division | 1 | 2000 | 788 | 0.010 |
Why?
| Cardiopulmonary Bypass | 1 | 2000 | 213 | 0.010 |
Why?
| Interleukin-4 | 1 | 1998 | 230 | 0.010 |
Why?
| Cell Death | 1 | 1999 | 345 | 0.010 |
Why?
| Vascular Resistance | 1 | 1999 | 374 | 0.010 |
Why?
| Renal Insufficiency | 1 | 2000 | 154 | 0.010 |
Why?
| Angiotensin-Converting Enzyme Inhibitors | 1 | 1998 | 228 | 0.010 |
Why?
| Ukraine | 1 | 1997 | 11 | 0.010 |
Why?
| Hypotension | 1 | 1998 | 135 | 0.010 |
Why?
| Endocarditis, Bacterial | 1 | 1997 | 38 | 0.010 |
Why?
| Models, Structural | 1 | 1996 | 38 | 0.010 |
Why?
| Lung Volume Measurements | 1 | 1996 | 51 | 0.010 |
Why?
| Radiometry | 1 | 1997 | 45 | 0.010 |
Why?
| Calcinosis | 1 | 2000 | 292 | 0.010 |
Why?
| Odds Ratio | 1 | 2000 | 1043 | 0.010 |
Why?
| Epidemiologic Methods | 1 | 1997 | 75 | 0.010 |
Why?
| Ultrasonography, Doppler, Transcranial | 1 | 1996 | 35 | 0.010 |
Why?
| Histocompatibility Antigens Class II | 1 | 1998 | 397 | 0.010 |
Why?
| Transfection | 1 | 1998 | 909 | 0.010 |
Why?
| Health Care Costs | 1 | 2000 | 414 | 0.010 |
Why?
| Cardiac Output, Low | 1 | 1996 | 78 | 0.010 |
Why?
| Urogenital Neoplasms | 1 | 1995 | 5 | 0.010 |
Why?
| Vital Capacity | 1 | 1996 | 277 | 0.010 |
Why?
| Equipment Failure | 1 | 1996 | 116 | 0.010 |
Why?
| Europe | 1 | 1997 | 369 | 0.010 |
Why?
| Neoplasms, Second Primary | 1 | 1997 | 91 | 0.010 |
Why?
| Pneumonia, Viral | 1 | 2001 | 361 | 0.010 |
Why?
| Blood Urea Nitrogen | 1 | 1995 | 60 | 0.010 |
Why?
| Models, Cardiovascular | 1 | 1996 | 183 | 0.010 |
Why?
| Interviews as Topic | 1 | 1997 | 601 | 0.010 |
Why?
| Acute Disease | 1 | 1998 | 984 | 0.010 |
Why?
| Heart Rate | 1 | 1999 | 756 | 0.010 |
Why?
| Child Development | 1 | 2000 | 449 | 0.010 |
Why?
| Heart Valve Prosthesis | 1 | 1997 | 126 | 0.010 |
Why?
| Aortic Aneurysm | 1 | 1995 | 67 | 0.010 |
Why?
| Hodgkin Disease | 1 | 1997 | 121 | 0.010 |
Why?
| Pain, Postoperative | 1 | 1997 | 214 | 0.010 |
Why?
| Forced Expiratory Volume | 1 | 1996 | 562 | 0.010 |
Why?
| Proportional Hazards Models | 1 | 1998 | 1184 | 0.010 |
Why?
| Equipment Design | 1 | 1996 | 533 | 0.010 |
Why?
| Waiting Lists | 1 | 1996 | 229 | 0.010 |
Why?
| Receptors, Antigen, T-Cell | 1 | 1998 | 656 | 0.010 |
Why?
| Biopsy | 1 | 1998 | 1090 | 0.010 |
Why?
| Reoperation | 1 | 1997 | 570 | 0.010 |
Why?
| Feasibility Studies | 1 | 1996 | 780 | 0.010 |
Why?
| Exercise Test | 1 | 1996 | 588 | 0.010 |
Why?
| Thyroid Neoplasms | 1 | 1997 | 277 | 0.010 |
Why?
| Cell Adhesion | 1 | 1994 | 454 | 0.010 |
Why?
| Ventricular Function, Right | 1 | 1995 | 262 | 0.010 |
Why?
| Myocardium | 1 | 1998 | 982 | 0.010 |
Why?
| Central Nervous System | 1 | 1994 | 244 | 0.010 |
Why?
| Patient Compliance | 1 | 1997 | 561 | 0.010 |
Why?
| Smoking | 1 | 2000 | 1556 | 0.010 |
Why?
| Blood Pressure | 1 | 1998 | 1713 | 0.010 |
Why?
| Diabetes Mellitus | 1 | 2000 | 985 | 0.010 |
Why?
| Research Design | 1 | 1997 | 1002 | 0.010 |
Why?
| Head and Neck Neoplasms | 1 | 1995 | 475 | 0.010 |
Why?
| Receptors, Lymphocyte Homing | 1 | 1990 | 16 | 0.010 |
Why?
| Lymphocyte Cooperation | 1 | 1990 | 54 | 0.010 |
Why?
| Thymectomy | 1 | 1990 | 15 | 0.010 |
Why?
| Antilymphocyte Serum | 1 | 1990 | 67 | 0.010 |
Why?
| Immunotherapy | 1 | 1994 | 504 | 0.010 |
Why?
| Antigens, Surface | 1 | 1990 | 166 | 0.010 |
Why?
| Infectious Bovine Rhinotracheitis | 1 | 1989 | 1 | 0.010 |
Why?
| Phorbol Esters | 1 | 1989 | 18 | 0.010 |
Why?
| Ionomycin | 1 | 1989 | 27 | 0.010 |
Why?
| Kidney | 1 | 1997 | 1355 | 0.010 |
Why?
| Ethers | 1 | 1989 | 17 | 0.010 |
Why?
| Receptors, Interleukin-2 | 1 | 1989 | 73 | 0.010 |
Why?
| Isoantigens | 1 | 1988 | 20 | 0.010 |
Why?
| Cell-Free System | 1 | 1988 | 53 | 0.010 |
Why?
| Cytotoxicity, Immunologic | 1 | 1989 | 204 | 0.010 |
Why?
| Surveys and Questionnaires | 1 | 2000 | 4882 | 0.000 |
Why?
| Cattle | 1 | 1989 | 994 | 0.000 |
Why?
| Breast Neoplasms | 1 | 1997 | 1994 | 0.000 |
Why?
| Models, Biological | 1 | 1988 | 1756 | 0.000 |
Why?
|
|
Weinberg's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|